Fig. 7: OSMI-1 treatment improved the therapeutic effects of BTZ in vivo. | Acta Pharmacologica Sinica

Fig. 7: OSMI-1 treatment improved the therapeutic effects of BTZ in vivo.

From: Inhibition of CDC27 O-GlcNAcylation coordinates the antitumor efficacy in multiple myeloma through the autophagy-lysosome pathway

Fig. 7

a Experimental scheme showing the xenograft model and combined MM treatment in this study (n = 9 in the vehicle group, n = 8 in the OSMI-1-treated group, n = 7 in the BTZ-treated group, and n = 8 in the OSMI-1 combined with BTZ-treated group). b Representative images and flow cytometry analysis of the percentages of hCD138+ MM.1S cells in the peritoneal lavage fluid and bone marrow of recipient NSG mice as indicated. c Representative images and flow cytometry analysis of hCDC27+ subsets within hCD138+ MM.1S cells in the peritoneal lavage fluid and bone marrow of recipient NSG mice are shown as indicated. d Diagram shows the research hypothesis of this study. The data are presented as the means ± SD. One-way ANOVA with Tukey’s multiple comparison test was used in b, c. ns: not significant. *P < 0.05, **P < 0.01, ***P < 0.001.

Back to article page